Previous 10 | Next 10 |
home / stock / lexxw / lexxw news
(TheNewswire) - DehydraTECH TM Powers Amari’s Award-Winning Products Click Image To View Full Size Kelowna, British Columbia – TheNewswire - April 14, 2021 – Lexaria Bioscience Corp....
DehydraTECH TM Powers Amari's Award-Winning Products KELOWNA, BC / ACCESSWIRE / April 14, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announced that its corporate client Amari Corp....
Undertaking new 2021 R&D programs in additional drug markets with combined market potential of $87 Billion. KELOWNA, BC / ACCESSWIRE / April 6, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug deliv...
(TheNewswire) - DehydraTECH TM CBD-Beverage Demonstrates 93.4% Potency One Year After Production - Lexaria’s Nanoemulsification Processing Technique Ensures Content Uniformity and Homogeneity of CBD Distribution Without Need for Physi...
DehydraTECH TM CBD-Beverage Demonstrates 93.4% Potency One Year After Production Lexaria's Nanoemulsification Processing Technique Ensures Content Uniformity and Homogeneity of CBD Distribution Without Need for Physical Mixing KELOWNA, BC / ACCESSWIRE / March 24, 2021 / Lexaria ...
(TheNewswire) Lexaria recently announced progress on its hypertension R&D program, consisting of three human clinical and two animal studies, as well as two studies in its antiviral drug evaluation program Kelowna, British Columbia &...
(TheNewswire) - Two of the four planned studies progressing to examine DehydraTECH™ with antivirals targeting SARS-CoV-2 / COVID-19 Kelowna, British Columbia - TheNewswire - March 16, 2021 – Lexaria Bioscien...
Five studies underway to examine DehydraTECH TM CBD for Hypertension. KELOWNA, BC / ACCESSWIRE / March 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces extensive progress i...
Lexaria recently expanded its hypertension R&D program evaluating effectiveness of DehydraTECH-processed CBD to three human clinical studies and two animal studies KELOWNA, BC / ACCESSWIRE / March 11, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Comp...
(TheNewswire) Kelowna, British Columbia – TheNewswire - February 16, 2021 – Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”),...
News, Short Squeeze, Breakout and More Instantly...
Lexaria Bioscience Corp. Warrant Company Name:
LEXXW Stock Symbol:
NASDAQ Market:
Lexaria Bioscience Corp. Warrant Website:
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced the receipt of interim results from the first four weeks of dosing in its ongoing diabetes animal study WEIGHT-A24-1. The company noted that the results have already produced several notewort...
(TheNewswire) DehydraTECH appears to work with a second GLP-1 drug – liraglutide DehydraTECH appears to be working with semaglutide both with and without SNAC technology DehydraTECH-CBD is showing strong apparent performance relative to GLP-1 D...
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug-delivery platforms, is preparing for growth by executing a strategic growth plan. A key element of the plan includes expanding the company’s management team to enable efficient handling of a greater workload of projects ...